Nathalie Roxanne Javidi-Sharifi, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
The timeline below shows the dates (blue tick marks) of publications associated with Nathalie Javidi-Sharifi's top concepts. The average publication date for each concept is shown as a red circle, illustrating changes in the primary topics that Nathalie Javidi-Sharifi has written about over time.
Receptor, Fibroblast Growth Factor, Type 3Fibroblast Growth Factor 2Gastrointestinal Stromal TumorsProto-Oncogene Proteins c-kitPyrimidinesLeukemia, Myeloid, AcuteProtein Kinase InhibitorsExosomesMesenchymal Stem CellsReceptor, Fibroblast Growth Factor, Type 1Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsLeukemia, Myeloid, Chronic-PhaseNiacinamidePyrazolesLeukemia, Lymphocytic, Chronic, B-CellPiperidines
To see the data from this visualization as text,
click here.
Name | Number of Publications | First Publication Year | Most Recent Publication Year | Average Publication Date |
Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2014 | 2014 | June 2014 |
Fibroblast Growth Factor 2 | 3 | 2014 | 2019 | August 2016 |
Gastrointestinal Stromal Tumors | 2 | 2014 | 2018 | October 2016 |
Proto-Oncogene Proteins c-kit | 2 | 2014 | 2018 | October 2016 |
Pyrimidines | 3 | 2014 | 2024 | October 2017 |
Leukemia, Myeloid, Acute | 2 | 2016 | 2019 | November 2017 |
Protein Kinase Inhibitors | 6 | 2014 | 2024 | February 2018 |
Exosomes | 1 | 2019 | 2019 | February 2019 |
Mesenchymal Stem Cells | 1 | 2019 | 2019 | February 2019 |
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 2019 | February 2019 |
Antineoplastic Agents | 3 | 2014 | 2024 | January 2020 |
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 2021 | October 2021 |
Leukemia, Myeloid, Chronic-Phase | 1 | 2021 | 2021 | October 2021 |
Niacinamide | 1 | 2021 | 2021 | October 2021 |
Pyrazoles | 2 | 2021 | 2024 | February 2023 |
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2024 | 2024 | May 2024 |
Piperidines | 1 | 2024 | 2024 | May 2024 |